Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Mycoses. 2024 Mar;67(3):e13706. doi: 10.1111/myc.13706.
Fluconazole-resistant Candida parapsilosis is a matter of concern.
To describe fluconazole-resistant C. parapsilosis genotypes circulating across hospitals in Spain and Rome and to study their azole-resistance profile associated with ERG11p substitutions.
PATIENTS/METHODS: We selected fluconazole-resistant C. parapsilosis isolates (n = 528 from 2019 to 2023; MIC ≥8 mg/L according to EUCAST) from patients admitted to 13 hospitals located in five Spanish cities and Rome. Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp susceptibility.
Of the 53 genotypes found, 49 harboured the Y132F substitution, five of which were dominating city-specific genotypes involving almost half the isolates. Another genotype involved isolates harbouring the G458S substitution. Finally, we found two genotypes with the wild-type ERG11 gene sequence and one with the R398I substitution. All isolates were fully susceptible/wild-type to amphotericin B, anidulafungin, micafungin and ibrexafungerp. The azole-resistance patterns found were: voriconazole-resistant (74.1%) or voriconazole-intermediate (25.2%), posaconazole-resistant (10%) and isavuconazole non-wild-type (47.5%). Fluconazole-resistant and voriconazole non-wild-type isolates were likely to harbour substitution Y132F if posaconazole was wild type; however, if posaconazole was non-wild type, substitution G458S was indicated if isavuconazole MIC was >0.125 mg/L or substitution Y132F if isavuconazole MIC was ≤0.125 mg/L.
We detected a recent clonal spread of fluconazole-resistant C. parapsilosis across some cities in Spain, mostly driven by dominating city-specific genotypes, which involved a large number of isolates harbouring the Y132F ERG11p substitution. Isolates harbouring substitution Y132F can be suspected because they are non-susceptible to voriconazole and rarely posaconazole-resistant.
氟康唑耐药近平滑念珠菌是一个值得关注的问题。
描述在西班牙和罗马的医院中流行的氟康唑耐药近平滑念珠菌基因型,并研究与 ERG11p 取代相关的唑类耐药谱。
患者/方法:我们从 2019 年至 2023 年入住西班牙五个城市和罗马的 13 家医院的患者中选择了氟康唑耐药近平滑念珠菌分离株(n=528;根据 EUCAST,MIC≥8mg/L)。此外,我们还测试了伏立康唑、泊沙康唑、伊曲康唑、两性霉素 B、米卡芬净、阿尼芬净和艾沙康唑的敏感性。
在所发现的 53 种基因型中,有 49 种携带 Y132F 取代,其中 5 种是涉及近一半分离株的具有优势的特定城市基因型。另一种基因型涉及携带 G458S 取代的分离株。最后,我们发现了两种具有野生型 ERG11 基因序列的基因型和一种具有 R398I 取代的基因型。所有分离株对两性霉素 B、阿尼芬净、米卡芬净和艾沙康唑均完全敏感/野生型。发现的唑类耐药模式为:伏立康唑耐药(74.1%)或伏立康唑中介(25.2%)、泊沙康唑耐药(10%)和伊曲康唑非野生型(47.5%)。如果泊沙康唑为野生型,则携带 Y132F 取代的氟康唑耐药和伏立康唑非野生型分离株很可能携带 Y132F 取代;然而,如果泊沙康唑为非野生型,如果伊曲康唑 MIC>0.125mg/L,则指示 G458S 取代,如果伊曲康唑 MIC≤0.125mg/L,则指示 Y132F 取代。
我们在西班牙的一些城市中检测到了氟康唑耐药近平滑念珠菌的近期克隆传播,主要由具有优势的特定城市基因型驱动,这些基因型涉及大量携带 Y132F ERG11p 取代的分离株。携带 Y132F 取代的分离株可能被怀疑,因为它们对伏立康唑不敏感,很少对泊沙康唑耐药。